Posted by Michael Wonder on 17 Aug 2020
Castration-resistant prostate cancer with a high risk of metastasis: enzalutamide has an additional benefit
17 August 2020 - New data from the PROSPER study shows benefit in overall survival.
As early as 2018 and 2019, the IQWiG examined whether enzalutamide offers adult men with non-metastatic, castration-resistant high-risk prostate cancer an advantage over the appropriate comparator therapy, i.e. over a wait-and-see approach while maintaining conventional androgen deprivation therapy (ADT).
On the basis of the first and second data cut-offs from the PROSPER study, an additional benefit was not proven. Since the study was still on-going, the Federal Joint Committee (G-BA) set a time limit for its decision.
After the deadline has expired, IQWiG reassessed enzalutamide on the basis of the third data cut-off from the study, which has now been completed. Now there is a hint of a considerable added benefit - mainly because of the longer overall survival of treatment with enzalutamide.
